TY - JOUR
T1 - Recent Advances in the Surfactant and Controlled Release Polymer-based Solid Dispersion
AU - Gupta, Aman
AU - Paudwal, Gourav
AU - Dolkar, Rigzin
AU - Lewis, Shaila
AU - Gupta, Prem N.
N1 - Funding Information:
The authors are grateful to the Director, CSIR-IIIM, Jammu, for supporting the research work in the area of solubility enhancement for poorly soluble drugs/drug discovery leads. The authors (GP and RD) acknowledge ICMR, New Delhi, and UGC New Delhi, respectively, for Research Fellowship. The manuscript number is CSIR-IIIM/IPR/00336.
Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022
Y1 - 2022
N2 - The oral route is the most preferred delivery route for drug administration due to its advantages, such as lower cost, improved patient compliance, no need for trained personnel, and less severity of drug reactions in general. The major problem with new molecules in the drug discovery pipeline is poor solubility and dissolution rate that ultimately results in low oral bioavailability. Numerous techniques are available for solubility and bioavailability (BA) enhancement, but out of all, solid dispersion (SD) is proven to be the most feasible due to fewer issues in manufacturing, processing, storage, and transportation. In the past few years, SD has been ex-tensively applied to reinforce the common issues of insoluble drugs. Currently, many hydrophobic and hydro-philic polymers are used to prepare either immediate release or controlled release SDs. Therefore, the biological behavior of the SDs is contingent upon the use of appropriate polymeric carriers and methods of preparation. The exploration of novel carriers and methodologies in SD technology leads to improved BA and therapeutic effectiveness. Moreover, the clinical applicability of SD-based formulations has been increased with the discovery of novel polymeric carriers. In this review, emphasis is laid down on the present status of recent genera-tions of SDs (i.e., surfactant and controlled release polymer-based SD) and their application in modifying the physical properties of the drug and modulation of pharmacological response in different ailments.
AB - The oral route is the most preferred delivery route for drug administration due to its advantages, such as lower cost, improved patient compliance, no need for trained personnel, and less severity of drug reactions in general. The major problem with new molecules in the drug discovery pipeline is poor solubility and dissolution rate that ultimately results in low oral bioavailability. Numerous techniques are available for solubility and bioavailability (BA) enhancement, but out of all, solid dispersion (SD) is proven to be the most feasible due to fewer issues in manufacturing, processing, storage, and transportation. In the past few years, SD has been ex-tensively applied to reinforce the common issues of insoluble drugs. Currently, many hydrophobic and hydro-philic polymers are used to prepare either immediate release or controlled release SDs. Therefore, the biological behavior of the SDs is contingent upon the use of appropriate polymeric carriers and methods of preparation. The exploration of novel carriers and methodologies in SD technology leads to improved BA and therapeutic effectiveness. Moreover, the clinical applicability of SD-based formulations has been increased with the discovery of novel polymeric carriers. In this review, emphasis is laid down on the present status of recent genera-tions of SDs (i.e., surfactant and controlled release polymer-based SD) and their application in modifying the physical properties of the drug and modulation of pharmacological response in different ailments.
UR - http://www.scopus.com/inward/record.url?scp=85134319119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134319119&partnerID=8YFLogxK
U2 - 10.2174/1381612828666220223095417
DO - 10.2174/1381612828666220223095417
M3 - Review article
C2 - 35209818
AN - SCOPUS:85134319119
SN - 1381-6128
VL - 28
SP - 1643
EP - 1659
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 20
ER -